check_circleStudy Completed

Multiple Sclerosis

BENEFIT Extension Study

Trial purpose

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Key Participants Requirements

Sex

Both

Age

23 - 50 Years


  • - All patients randomized and treated at least once in study 304747


  • - Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Trial summary

Enrollment Goal
283
Trial Dates
September 2007 - January 2011
Phase
N/A
Could I Receive a placebo
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, Canada
Completed
Many Locations, Switzerland
Completed
Many Locations, Hungary
Completed
Many Locations, Israel
Completed
Many Locations, Norway
Completed
Many Locations, Sweden
Completed
Many Locations, Austria
Completed
Many Locations, Belgium
Completed
Many Locations, Poland
Completed
Many Locations, Denmark
Completed
Many Locations, Slovenia
Completed
Many Locations, Czech Republic
Completed
Many Locations, Italy
Completed
Many Locations, Finland
Completed
Many Locations, Germany
Completed
Many Locations, France
Terminated
Many Locations, Netherlands
Completed
Many Locations, Spain

Primary Outcome

  • To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study
    date_rangeTime Frame:
    End of Study
    enhanced_encryption
    Safety Issue:
    No

Trial design

Extension study of the BENEFIT (304747) and BENEFIT follow-up (305207) studies to further evaluate the progress of patients with first demyelinating event suggestive of multiple sclerosis
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A